The Dow Jones Industrial Average climbed over 200 points on Monday, driven by strong gains in the healthcare and technology sectors. PROCEPT BioRobotics, Monte Rosa Therapeutics, and EyePoint Pharmaceuticals were among the top performers, fueled by positive financial results, licensing deals, and promising clinical trial data. Other notable movers include Revance Therapeutics, ImmunityBio, and Trump Media & Technology Group, while the Bitcoin surge boosted MicroStrategy and MARA Holdings.
Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) saw its stock skyrocket over 30% in premarket trading on Monday after announcing a global exclusive development and commercialization agreement with pharmaceutical giant Novartis AG (NYSE: NVS) for its VAV1 MGDs, including MRT-6160. The deal grants Novartis worldwide rights to develop and commercialize the drug, which is currently in Phase 1 clinical trials for immune-mediated conditions. The partnership highlights the potential of MRT-6160, a novel drug targeting a key signaling protein involved in immune responses, and its promising future in treating various immune-related diseases.
